of questions of safety [10%;:50 mL/minute: No dosage adjustment necessary. CrCl 31 to 50 mL/minute: 1.25 g every 8 hours CrCl 16 to 30 mL/minute: 0.94 g every 12 hours CrCl 6 to 15 mL/minute: 0.94 g every 24 hours CrCl 5 mL/minute: 0.94 g every 48 hours End stage renal disease (ESRD) on intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days; base dose upon patient's estimated renal function (eg, CrCl 6 to 15 mL/minute or CrCl 5 mL/minute). Approximately 55% (based on a ceftazidime 1 g dose and avibactam 100 mg dose) is removed following a 4-hour dialysis session. Dosing: Hepatic Impairment No dosage adjustment necessary. Reconstitution IV: Reconstitute vial with 10 mL of NS, D5W, SWFI or other compatible solution listed in the manufacturer s labeling (resulting approximate concentration: ceftazidime 167 mg/mL and avibactam 42 mg/mL) and further dilute in 50 to 250 mL of a compatible IV infusion fluid; mix gently. Solution ranges in color from clear to light yellow. Administration IV: Administer by intermittent infusion over 2 hours. Storage Vials: Store intact vials at 25 C (77 F); excursions permitted between 15 C and 30 C (59 F and 86 F). Protect from light. After reconstitution, contents of the vial should be transferred within 30 minutes to an infusion bag for further dilution. Intermittent IV infusion: Admixed solutions in NS, D5W, LR, or any combination of dextrose and sodium chloride injection containing up to dextrose 2.5% and sodium chloride 0.45% are stable up to 12 hours at room temperature and 24 hours at 2 C to 8 C (36 F to 46 F). Use solutions previously stored at 2 C to 8 C (36 F to 46 F) within 12 hours of subsequent storage at room temperature. Drug Interactions Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. Monitor therapy BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy Chloramphenicol: May diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure. Consider therapy modification Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Avoid combination Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy Probenecid: May increase the serum concentration of Avibactam. Avoid combination Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification Teriflunomide: May increase the serum concentration of OAT3 Substrates. Monitor therapy Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Monitor therapy Test Interactions Ceftazidime: Positive direct Coomb. False-positive reaction for urine glucose with certain methods; use glucose tests based on enzymatic glucose oxidase reactions. Adverse Reactions 1% to 10%: Gastrointestinal: Diarrhea (3%), nausea (3%), constipation (2%), upper abdominal pain (1%) Hematologic & oncologic: Positive direct coombs test (3%; no hemolytic anemia reactions reported)] Drug Status Rx Availability Prescription only B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Avibactam / ceftazidime Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Drug Class Cephalosporins / beta-lactamase inhibitors Related Drugs cephalosporins / beta-lactamase inhibitors Avycaz , Zerbaxa , ceftolozane / tazobactam , avibactam / ceftazidime Kidney Infections ciprofloxacin , cephalexin , Augmentin , Levaquin , Keflex , levofloxacin , Bactrim , More... Urinary Tract Infection ciprofloxacin , amoxicillin , doxycycline , Augmentin , Levaquin , levofloxacin , Bactrim , More... Intraabdominal Infection ciprofloxacin , metronidazole , clindamycin , ceftriaxone , Flagyl , Rocephin , gentamicin , More... incidentally
mother or father Ceftazidime and Avibactam profits
EmoticonEmoticon